779 patents
Page 12 of 39
Utility
Chemical Compounds
3 Nov 22
Ariamala Gopalsamy, Shawn Cabral, Agustin Casimiro-Garcia, Ming Zhu Chen, Chulho Choi, Robert Lee Dow, Olugbeminiyi Omezia Fadeyi, David Hepworth, Jayasankar Jasti, Lyn Howard Jones, Arjun Venkat Narayanan, Mihir Dineshkumar Parikh, David Walter Piotrowski, Lee Richard Roberts, Ralph Pelton Robinson, Jr., Hatice Gizem Yayla
Filed: 12 Apr 21
Utility
Chimeric Antigen Receptors Targeting B-cell Maturation Antigen
27 Oct 22
The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen).
Tracy Chia-Chien KUO, Bijan Andre Boldajipour, Javier Fernando Chaparro Riggers, Philippe Duchateau, Roman Galetto, Alexandre Juillerat, Thomas Charles Pertel, Arvind Rajpal, Barbra Johnson Sasu, Cesar Adolfo Sommer, Julien Valton, Thomas John Van Blarcom
Filed: 15 Mar 22
Utility
Diacylglycerol acyl transferase 2 inhibitor
18 Oct 22
David James Edmonds, Kevin James Filipski, Kentaro Futatsugi, Michelle Renee Garnsey, Jack Chang Hung Lee, Daniel Jonathan Smaltz
Filed: 5 Oct 20
Utility
Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
18 Oct 22
Shane M. Walls, Li Ren, Ginelle A. Ramann, David A. Moreno, Andrew T. Metcalf, Elizabeth A. McFaddin, Gabrielle R. Kolakowski, James F. Blake, Donghua Dai, Julia Haas, Yutong Jiang, Dean Kahn
Filed: 18 Jan 19
Utility
Tricyclic compounds and their use as phosphodiesterase inhibitors
18 Oct 22
Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Travis T. Wager, Ramalakshmi Yegna Chandrasekaran
Filed: 9 Jun 16
Utility
Pyrazolo[1,5-a]pyrazin-4-yl derivatives
18 Oct 22
Matthew Frank Brown, Alpay Dermenci, Andrew Fensome, Brian Stephen Gerstenberger, Matthew Merrill Hayward, Dafydd Rhys Owen, Stephen Wayne Wright, Li Huang Xing, Xiaojing Yang
Filed: 8 Sep 20
Utility
Unknown
18 Oct 22
In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof.
Annaliesa Sybil Anderson, Susan Kay Hoiseth, Kathrin Ute Jansen, Justin Keith Moran, Mark Edward Ruppen
Filed: 30 Sep 20
Utility
Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
18 Oct 22
The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand 1A(TL1A) The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same.
Robert Arch, Jun Zhang, Michelle Mader, Tetsuya Ishino, Joel Bard, William Finlay, Orla Cunningham, Ciara Reilly, Peter Brams, Brigitte Devaux, Haichun Huang, Karla Henning
Filed: 24 May 19
Utility
Cancer Vaccines
13 Oct 22
The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.
Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
Filed: 13 May 21
Utility
3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES As Mek Inhibitors
13 Oct 22
Shelley ALLEN, Patrick Michael DOERNER BARBOUR, James Francis BLAKE, Sydney Taylor BLANCHE, Mark Laurence BOYS, Wesley Dewitt CLARK, Connor James COWDREY, Joshua Ryan DAHLKE, Alex Andrew KELLUM, Ellen Margaret KNAPP, David Austin MORENO, Jacob Matthew O'LEARY, Li REN, Faith Elizabeth WITKOS
Filed: 30 Mar 22
Utility
CDK2/4/6 Inhibitors
13 Oct 22
Douglas Carl Behenna, Ping Chen, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Mehran Jalaie, Asako Nagata, Sajiv Krishnan Nair, Sacha Ninkovic, Martha Alicia Ornelas, Cynthia Louise Palmer, Eugene Yuanjin Rui
Filed: 15 Jun 22
Utility
Combination of a PD-1 Antagonist and a Vegfr Inhibitor for Treating Cancer
13 Oct 22
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
Jean-Francois Andre MARTINI, Jamal Christo Tarazi, Rodolfo Fleury Perini, David J. Mauro
Filed: 20 Apr 22
Utility
Improvements to Wash Solutions for Protein a Chromatography In an Antibody Purification Process
6 Oct 22
The invention relates to a Protein A chromatography step of a purification process for a therapeutic protein, wherein a load solution including the therapeutic protein is applied onto a Protein A chromatography medium.
Russell Ian SHPRITZER
Filed: 9 Jun 20
Utility
Substituted PYRAZOLO[1,5-A]PYRIDINE Compounds As Ret Kinase Inhibitors
6 Oct 22
Steven W. ANDREWS, Sean ARONOW, James F. BLAKE, Barbara J. BRANDHUBER, James COLLIER, Adam COOK, Julia HAAS, Yutong JIANG, Gabrielle R. KOLAKOWSKI, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Oren T. MCNULTY, Andrew T. METCALF, David A. MORENO, Ginelle A. RAMANN, Tony P. TANG, Li REN, Shane M. WALLS
Filed: 1 Dec 20
Utility
Anti-IL-2 antibodies and compositions and uses thereof
4 Oct 22
The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ.
Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
Filed: 9 Jul 20
Utility
Modulators of STING (Stimulator of Interferon Genes)
29 Sep 22
Ketan Satish GAJIWALA, Chan Woo HUH, Mehran JALAIE, Ryan Lloyd PATMAN, Eugene Yuanjin RUI, Jianmin SUN, Martin James WYTHES
Filed: 11 Mar 22
Utility
Nitrile-containing antiviral compounds
27 Sep 22
Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Qingyi Yang
Filed: 22 Apr 22
Utility
Methods of treating neurofibromatosis with N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
27 Sep 22
The present disclosure relates to: a) a crystalline composition of essentially pure Form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising the crystalline composition of essentially pure Form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier; and c) methods of treating a tumor, a cancer, or a Rasopathy disorder by administering the crystalline composition of essentially pure Form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof.
Erwin Irdam
Filed: 24 Jun 21
Utility
KRas G12D inhibitors
27 Sep 22
Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P. A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
Filed: 27 Aug 20
Utility
Compounds for the Treatment of Braf-associated Diseases and Disorders
15 Sep 22
Patrick Michael DOERNER BARBOUR, Tanna Marie BETTENDORF, Dean Russell KAHN, Alex Andrew KELLUM, Ellen Ruth LAIRD, David Austin MORENO, Li REN
Filed: 4 Jun 21